NCT01974817View on ClinicalTrials.gov

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
End Stage Renal Disease
Interventions
BIOLOGICAL

13-valent conjugate pneumococcal vaccine

0.5ml IM for one dose

Trial Locations (1)

48195

Sparrow Dialysis at Saint Lawrence Campus, Lansing

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Michigan State University

OTHER

NCT01974817 - Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease | Biotech Hunter | Biotech Hunter